TY  - JOUR
A1  - Knoll, Nina
A1  - Wiedemann, Amelie U.
A1  - Schrader, Mark
A1  - Felber, Juliane
A1  - Burkert, Silke
A1  - Daig, Isolde
A1  - Heckhausen, Jutta
T1  - Calibrating Independence Goals and Partner Support: Couples Adjust to Functional Limitations after Tumor Surgery
JF  - Applied psychology : Health and well-being
N2  - When patients recover from disease-related functional limitations, support received from partners may not always match patients' changing independence goals. The lines of defense (LoD) model proposes a hierarchy of independence goals (LoDs), ranging from minimising discomfort by disengagement (lowest LoD) to protection of self-reliance (highest LoD). Prostate cancer patients' LoDs were examined as moderators of the association between partner support and patients' and partners' affect during patients' recovery from postsurgical functional limitations. MethodsData from 169 couples were assessed four times within 7months following patients' surgery. Patients reported on post-surgery functional limitations (i.e. incontinence), LoDs, affect, and received partner support. Partners reported on affect and support provided to patients. ResultsIn patients endorsing lower LoDs, more received support was associated with less negative affect. Also, not endorsing high LoDs while receiving strong partner support was related to patients' lower negative and higher positive affect. Partners' support provision to patients tended to be associated with increases in partners' negative affect when patients had endorsed higher LoDs and with increases in positive affect when patients had endorsed lower LoDs. Matching patients' independence goals or LoDs with partners' support may be beneficial for patients' and partners' affect.
KW  - couples
KW  - independence goals
KW  - lines of defense
KW  - prostate cancer
KW  - social support
Y1  - 2015
U6  - https://doi.org/10.1111/aphw.12043
SN  - 1758-0846
SN  - 1758-0854
VL  - 7
IS  - 2
SP  - 167
EP  - 187
PB  - Wiley-Blackwell
CY  - Hoboken
ER  - 
TY  - GEN
A1  - Kühn, Tilman
A1  - Floegel, Anna
A1  - Sookthai, Disorn
A1  - Johnson, Theron
A1  - Rolle-Kampczyk, Ulrike
A1  - Otto, Wolfgang
A1  - von Bergen, Martin
A1  - Boeing, Heiner
A1  - Kaaks, Rudolf
T1  - Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study
T2  - BMC medicine
N2  - Background:
First metabolomics studies have indicated that metabolic fingerprints from accessible tissues might
be useful to better understand the etiological links between metabolism and cancer. However, there is still a lack
of prospective metabolomics studies on pre-diagnostic metabolic alterations and cancer risk.
Methods:
Associations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids,
biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal
cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835
incident cancer cases.
Results:
The median follow-up duration was 8.3 years among non-cases and 6.5 years among incident cases of
cancer. Higher levels of lysophosphatidylcholines (lysoPCs), and especially lysoPC a C18:0, were consistently related
to lower risks of breast, prostate, and colorectal cancer, independent of background factors. In contrast, higher
levels of phosphatidylcholine PC ae C30:0 were associated with increased cancer risk. There was no heterogeneity
in the observed associations by lag time between blood draw and cancer diagnosis.
Conclusion:
Changes in blood lipid composition precede the diagnosis of common malignancies by several years.
Considering the consistency of the present results across three cancer types the observed alterations point to a
global metabolic shift in phosphatidylcholine metabolism that may drive tumorigenesis.
T3  - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe - 437 
KW  - metabolomics
KW  - epidemiology
KW  - breast cancer
KW  - prostate cancer
KW  - colorectal cancer
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-407258
ER  -